Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.44 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828961 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3AKT1 | |
| SCHEMBL4827617 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3AKT1 | |
| SCHEMBL1506494 | 0.90 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL23497746 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 | |
| Trifluoroacetic Acid SCHEMBL29990705 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 | |
| Trifluoroacetic Acid SCHEMBL29744405 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 | |
| Trifluoroacetic Acid SCHEMBL23498067 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 | |
| SCHEMBL4827560 | 0.85 | CHRNB4 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4826229 | 0.83 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 | |
| SCHEMBL4826782 | 0.83 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | claimed |
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | claimed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | claimed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | claimed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | claimed |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| CN-1636990-A | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LAB (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | CHRNB2 31/4885CHRNA4 19/4885CHRNB4 38/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | CHRNB2 31/4885CHRNA4 19/4885CHRNB4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.